Radioimmunotherapy: Principles, current trends and future directions

Hellenic Journal of Nuclear Medicine

Volumn 7, Issue 1, 2004, Pages 39-43

  Karagiannis, Tom C ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

131I; Bexxar; Non Hodgkin's lymphoma; Radioimmunotherapy; Zevalin

Indexed keywords

IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; RITUXIMAB; TOSITUMOMAB I 131; YTTRIUM 90;

B CELL LYMPHOMA; BLOOD TOXICITY; CANCER REGRESSION; CANCER THERAPY; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; HUMAN; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 2542479883     PISSN: 00258024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Ehrlich P. Collected studies on immunity. Balduon C. (ed, translated), Wiley Inc, New York, USA, 1906.
2. Pressman D, Keighley G. The zone of activity of antibodies as determined by the use of radioactive tracers; the zone of activity of nephritoxic anti-kidney serum. J Immunol 1948, 59: 141-149.
3. Order SE. The history and progress of serologic immunotherapy and radio-diagnosis. Radiology 1976, 118: 219-223.
4. Beierewaltes WH. The history of the use of radioactive iodine. Sem Nucl Med 1979, 9: 151-162.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256: 495-497.
6. Gottstein C, Winkler U, Bohlen H, et al. Immunotoxins: is there a clinical value? Ann Oncol 1973, 1: 97-103.
7. Eichler HG. Clinical experience of targeted therapy. Biotherapy 1991, 3: 77-85.
8. Blakey DC. Drug targeting with monoclonal antibodies. A review. Acta Oncol 1992, 31: 91-97.
9. Matzku S. Monoclonal antibodies in tumor therapy. In: Systemic radiotherapy with monoclonal antibodies, options and problems, Bihl SML, Bihl H, Wannenmacher M (eds). Springer-Verlag, Berlin, Heidelberg, Germany, 1996, p. 1-8.
10. Jones PT, Dear PH, Foot J, et al. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 1986, 321: 522-525.
11. Winter G, Harris WJ. Humanized antibodies. Immunol Today 1993, 14: 243-246.
12. Meredith RF, LoBuglio AF, Plott WE. Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1, k17-1A monoclonal antibody. J Nucl Med 1991, 32: 1162-1168.
13. Malloney DG. Mechanism of action of rituximab. Anticancer Drugs 2001, 12: S1-S4.
14. 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans. Cancer Res 1991, 51: 5461-5466.
15. Link BK. Monoclonal antibody therapy in non-Hodgkin's lymphoma: an overview. Bloodline Rev 2001, 1: 3-4.
16. Kawamoto T, Sato JD, Le A, et al. Growth stimulation of A431 cells by epidermal growth factor: identification of high affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci 1983, 80: 1337-1341.
17. Sato JD, Kawamoto T, Le AD, et al. Biological effects in vitro of monoclonal antibody to human epidermal growth factor receptors. Mol Biol Med 1983, 1: 511-529.
18. Mendelsohn J. Potential clinical application of anti-EGF receptor monoclonal antibodies. In: Cancer cells, Furth M, Greaves M. (eds), Cold Spring Harbor Press, New York, USA, 1989, p. 359-362.
19. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997, 3: 2703-2707.
20. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000, 89: 74-82.
21. Peng D, Fan Z, Lu Y, et al. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1987, 56: 3667-3669.
22. Cumber AJ, Forrester JA, Foxwell BMJ, et al. Preparation of antibody-toxin conjugates. Methods in Enzymology 1985, 112: 207-225.
23. Neville DM, Srinivasachar K, Stone R, et al. Enhancement of immunotoxin efficacy by acid-cleavable cross-linking agents utilizing diptheria toxin and toxin mutants. J Biol Chem 1989, 264: 14653-14661.
24. Faulstich H, Fiume L. Protein conjugates of fungal toxins. Methods in Enzymology 1985, 112: 225-237.
25. Raso V, Basala M. A highly cytotoxic human transferrin-ricin A' chain conjugate used to select receptor-modified cells. J Biol Chem 1984, 259: 1143-1149.
26. Hurwitz E, Maron R, Arnon R, et al. The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities. Cancer Res 1975, 35: 1175-1181.
27. Berzci A, Ruthner M, Szuts V, et al. Influence of conjugation of doxorubicin to transferrin on the iron uptake by K562 cells via receptor-mediated endocytosis. Eur J Biochem 1993, 213: 427-436.
28. Willner D, Trail PA, Hofstead SJ, et al. (6-Maleimadocaproyl) hydrazone of doxorubicin - a new derivative for the preparation of immuno-conjugates of doxorubicin. Bioconjugate 1993, 4: 521-527.
29. Tsukada Y, Kato Y, Umemoto N, et al. An anti-α-fetoprotein antibody-daunomycin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier. J Natl Cancer Inst 1984, 73: 721-729.
30. Mandler R, Wu C, Sausville EA, et al. Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines. J Natl Cancer Inst 2000, 92: 1573-1581.
31. Hertz S, Roberts A, Jackson H. Radioactive iodine as an indicator in the study of thyroid physiology. Proc Soc Exp Biol Med 1938, 38: 510-513.
32. Hamilton TA, Wada HG, Sussman HH. Identification of transferrin receptor on the surface of humam cultured cells. Proc Natl Acad Sci US 1979, 76: 6406-6410.
33. Hertz S, Roberts A. Application of radioactive iodine in therapy of Grave's disease. J Clin Invest 1942, 21: 124.
34. Pressman D, Korngold L. The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 1953, 6: 619-623.
35. Order SE, Ettinger JL, Alderson P. Phase I-II study of radiolabelled antibody integrated in the treatment of primary hepatic malignancies. Int J Radiat Oncol Biol Phys 1980, 6: 703-710.
36. Order SE, Klein JL, Ettinger D. Use of isotopic immunoglobulin in therapy. Cancer Res 1983, 40: 3001-3007.
37. Leichner PK, Kein JL, Siegelman SS. Dosimetry of iodine-131 labelled antiferritin in hepatoma. Specific activities in the tumor and liver. Cancer Treat Rep 1981, 67: 647-658.
38. Breitz HB. How far have we come with solid (nonhematologic) tumor radioimmunotherapy? J Nucl Med 2000, 41: 2011-2014.
39. Humm JL. Problems and advances in the dosimetry of radionuclide targeted therapy. In: Systemic radiotherapy with monoclonal antibodies, options and problems, Bihl SML, Bihl H, Wannenmacher M (eds.) Springer-Verlag, Berlin, Heidelberg, Germany, 1996, p. 37-66.
40. Wiseman GA. Radioimmunotherapy agents: what they are and how they work. Bloodline Rev 2001, 1: 5-6.
41. White AC. Rituximab immunotherapy for non-Hodgkin's lymphoma. Cancer Biother Radiopharm 1999, 4: 241-50.
42. Goldenberg DM. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy. Crit Rev Oncol Hematol 2001, 39: 195-201.
43. Wiseman GA, White CA, Witzig TE, et al. Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res 1999, 5: 3281s-3286s.
44. Gordon LI, Witzig TE, Wiseman GA, et al. Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol 2002, 29: 87-92.
45. 131I-labelled monoclonal antibodies? Some dosimetric considerations. In: Systemic radiotherapy with monoclonal antibodies, options and problems, Bihl SML, Bihl H, Wannenmacher M (eds). Springer-Verlag, Berlin, Heidelberg, Germany, 1996, p. 67-76.
46. Press OW, Eary JF, Gooley T, et al. A phase I/III trial of iodine-131-tositumomab (anti-CD20), etoposide and cyclophosphamide, and autologous stem cell transplantation in patients with relapsed B-cell lymphomas. Blood 2000, 96: 2934-2942.
47. Wiseman GA, White CA, Sparks RB, et al. Biodistibution and dosimetry results from a phase III randomized control trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. Crit Rev Oncol Hematol 2001, 39: 181-194.
48. Wiseman GA, White CA, Stabin M, et al. Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiutexan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med 2000, 27: 766-777.
49. Witzig TE. Radioimmunotherapy in patients with non-Hodgkin's lymphoma refractory to chemotherapy and immunotherapy. Bloodline Rev 2001, 1: 9-10.
50. Cheson BD. Radioimmunotherapy in hematologic malignancies: future directions. Bloodline Rev 2001, 1: 11-12.
51. Schroff RW, Foon KA, Beatty SM, et al. Human antimurine immunoglobulin responses in patients receiving MoAb therapy. Cancer Res 1985, 45: 879-885.
52. Jain RK. Transport of macromolecules across tumor vasculature. Cancer Metastas Rev 1987, 6: 559-594.
53. Jain RK. Determinants of tumor blood flow. A review. Cancer Res 1988, 48: 2641-2658.
54. Jain RK, Baxter LT. Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors. Significance and elevated interstitial pressure. Cancer Res 1988, 48: 7022-7032.
55. Swabb EA, Wei J, Gullino PM. Diffusion and convection in normal and neoplastic tissues. Cancer Res 1974, 34: 2814-2822.
56. Sutherland R, Buchegger F, Schreyer M, et al. Penetration and binding of radiolabelled anti-carcinoembryonic antigen MoAbs and their antigen binding fragments in human colon multicellular tumour spheroids. Cancer Res 1987, 47: 1627-1633.
57. Adams GP, Schier R, McCall AM, et al. Prolonged in vivo tumor retention of a human diabody targeting the extracellular domain of human HER2/neu. Br J Cancer 1998, 77: 1405-1412.
58. Winthrop MD, DeNardo SJ, DeNardo GL. Development of a hyperimmune anti-MUC-1 single chain antibody fragments phage display library for targeting breast cancer. Clin Cancer Res 1999, 5: 3088s-3094s.
59. Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review "Of Mice and Men". Hybridoma 1997, 16: 101-107.
60. Behr TM, Salib AL, Liersch T, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res 1999, 5: 3232s-3242s.
61. Mahe MA, Fumoleau P, Fabbro M, et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin Cancer Res 1999, 5: 3249s-3253s.
62. Boerman OC, van Schaijk FG, Oyen WJG, et al. Pretargeted radioimmunotherapy: progress step by step. J Nucl Med 2003, 44: 400-411.
63. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 2003, 52: 281-296.